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Background: Available literature suggests that provider adherence to best practice 
guidelines regarding the prescribing and management of opioid therapies is low. 
Documentation of patient screening for present or future opioid use disorder is 
inconsistent. Provider incorporation of evidence-based guidelines into routine patient care 
is essential to optimizing outcomes related to opioid use disorders.  
 
Purpose/Specific Aims: The purpose of this scholarly project was to facilitate 
recognition of patients at high risk for opioid use disorders and facilitate best evidence-
based practices in the care of this population. Specific aims were to achieve provider 
compliance with: patient risk screening, PDMP review, completion of signed care plans, 
and reduction of inappropriate opioid prescriptions.  
 
Methods: A quasi-experimental design was used for this quality improvement project. 
The sample included patients receiving treatment for acute or chronic pain, or who were 
identified as having a substance use disorder. The project was conducted at an internal 
medicine practice in the northeast region. The intervention included an educational 
program addressing the ASAM guidelines and ORT utilization with implementation of a 
SmartPhrase in Epic. Baseline data was collected for the two-month period preceding the 
intervention and post-intervention data was collected for the three-month period 
following the intervention. Differences in pre- and post- intervention results were 
analyzed using chi square. 
 
Results: This project resulted in improved compliance with the implementation of urine 
toxicology screening, PDMP review, and completion of a controlled substance 
agreement. Compliance with ORT was not achieved.  
 
Conclusion: This project led to an increase in compliance with best opioid prescribing 
practices. The ORT was not consistently implemented; however, the number of new 
opioid prescriptions remained negligible. Additional efforts will be necessary to maintain 
the progress achieved in this project including attention to continued provider education. 
Real-time auditing and feedback will also be incorporated, and opportunities to involve 
office staff will be explored. 
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IMPROVING COMPLIANCE WITH BEST PRACTICE STANDARDS FOR 
PATIENTS AT RISK FOR OPIOID USE DISORDER 
The prevalence of opioid use disorder (OUD) and subsequent related overdose 
rates have increased significantly over the last decade, resulting in considerable morbidity 
and mortality (Strain, 2018). Identification and implementation of strategies to mitigate 
the negative outcomes associated with OUD is essential. This scholarly project was 
designed to translate evidence-based guidelines on opioid prescribing into practice and to 
evaluate the effectiveness of the intervention on related processes and outcomes. 
Background and Significance  
Opioid use disorder is defined by the Center for Disease Control (CDC) as a 
problematic pattern of opioid use leading to clinically significant impairment (2018). 
Opioid use disorder has become a topic of national interest in the past decade, with 
aggressive reforms having been made to federal and state prescribing regulations. In the 
United States, there is an estimated incidence of opioid use disorder of two to sixteen 
million people (Barclay, Owens, & Blackhall, 2014; Reyes-Gibby, Anderson, & Todd, 
2010; Shuckit, 2016; Wei, et al., 2019). Over four million people have reported non-
medical use of prescription opioids in their lifetime (Rager & Schwartz, 2017; Schuckit, 
2016). Nearly half of patients who report the recreational use of opioids meet the criteria 
for a diagnosis of opioid use disorder based on the criteria according to the Diagnostic 
and Statistical Manual – Fifth Edition (DSM-V) (Rager & Schwartz, 2017; Shuckit, 
2016; Strain, 2018). According to the CDC (2018), opioid use disorder begins with a 
prescription medication in 62% of cases. These opioids are either prescribed for the 




Many patients who begin misusing prescription opioids later shift to illicit opioids, such 
as heroin, which is associated with a higher risk for overdose (Strain, 2018). Heroin is 
often mixed with the synthetic opioid, Fentanyl, which significantly increases the risk of 
overdose and mortality (NIDA, 2019).  
To address the epidemic of opioid use disorder, the National Academies of 
Sciences, Engineering and Medicine released the seminal report Pain Management and 
the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of 
Prescription Opioid Use (Bonnie, Ford, & Phillips, 2017). This report identified the need 
for broad intervention across various levels. Specifically, the report calls for the need to 
restrict supply, optimize prescribing practices, reduce demand, and reduce harm (Bonnie, 
et al., 2017). Optimization of prescribing practices is a primary responsibility of 
providers with authority to prescribe opioid medications. 
Evidence-based guidelines supporting best practices in opioid prescribing include 
patient screening for risk of opioid use disorder using a valid screening tool and provider 
implementation of a controlled substance agreement, review of the prescription drug 
monitoring program (PDMP), and monitoring of urine toxicology results for non-
prescribed substances for all patients receiving opioid medications (ASAM, 2015). 
Despite the development of national guidelines, provider compliance with these best 
practices is low, and data describing the effectiveness of interventions to achieve 
compliance with these best practices is limited (Naimer, Munro, Singh, & Permaul, 
2019). Therefore, there is a need for new evidence to support best practices in the 






Opioid Use Disorder and Opioid Misuse 
Opioid use disorder is a chronic relapsing condition that often occurs when an 
individual develops dependence on these medications. Opioids activate mu receptors, 
initiating intracellular communication by G protein stimulation (Strain, 2018). These 
receptors are present in the central and peripheral nervous system, with the stimulation of 
either causing different effects on the body. For example, central nervous system mu 
receptor stimulation results in physiologic responses such as respiratory depression, 
analgesia, euphoria, and miosis (Strain, 2018). Stimulation of the receptors within the 
peripheral nervous system results in physiologic responses such as cough suppression and 
opioid-induced constipation (Strain, 2018). Activation of both central and peripheral mu 
receptors may result in negative or positive effects, but adverse effects become more 
common with overuse.  
The DSM-V defines opioid use disorder as a problematic pattern of opioid use 
that leads to clinically significant impairment or distress (American Psychiatric 
Association, 2016). To meet diagnostic criteria for opioid use disorder, a patient must 
have at least two of the following characteristics: opioids taken in larger amounts than 
intended, persistent desire or unsuccessful attempts to reduce use, increased time spent 
attempting to obtain the substance, the development of cravings when the substance is not 
obtained, use leading to failures in work or home life, continued use despite clear social 
and interpersonal problems, and signs of tolerance or withdrawal without constant use 
(APA, 2016). The severity of the disease is based on how many of the above conditions 




 With continued use of the substance, tolerance may occur. As tolerance occurs, 
the patient becomes less responsive to the effects of the medication, eventually requiring 
a larger dose to achieve the same effect previously achieved with smaller doses (Strain, 
2018). The addictive nature of these medications may also lead to withdrawal symptoms 
when the medication is stopped. These include tearing eyes, rhinorrhea, yawning, muscle 
twitching, and hyperactive bowel sounds, cravings, and dysphoria (Strain, 2018). Opioid 
withdrawal symptoms are measured by healthcare clinicians using the Clinical Opiate 
Withdrawal Scale (COWS), which classifies severity of symptoms based on clinical 
presentation and self-reported symptoms (ASAM, 2015). The desire to avoid a state of 
withdrawal often leads to continued escalating use, which puts patients at highest risk for 
overdose.   
 The overall rate of OUD is estimated to be between two to sixteen million 
Americans (Chen, Hom, Richman, Asch, Podchiyska, & Johansen, 2016; Florence, Luo, 
Xu, & Zhou, 2016; Bonnie, Ford, & Phillips, 2017). The estimated prevalence of OUD 
among patients who were prescribed an opioid is 8%, and the estimated  incidence of 
combined misuse, OUD and aberrant behaviors ranges from 15-26% (Bonnie, et al., 
2017). The incidence of OUD among patients prescribed opioids for chronic pain is even 
higher at 21-29% (Vowles, McEntee, Julnes, Frohe, Ney, & van der Goes, 2015). Not 
only is the problem of OUD far reaching, but the incidence has continued to increase. In 
fact, Florence, et al., (2016), report that the incidence of OUD has increased by 200,000 
individuals since 2007.  
Opioid use disorder carries a significant cost burden. The cost associated with the 




without an opioid use disorder (Florence, Luo, Xu, & Zhou, 2016). These authors further 
estimated the aggregate cost of OUD to be between $70-$80 billion (Florence, et al., 
2016). 
Screening Tools 
As opioid use disorders are becoming more prevalent, screening tools are being 
developed to identify risk among populations of all ages, genders, and risk factors. These 
screening tools are imperative in better understanding aberrant drug-related behaviors to 
assist providers in recognizing early signs of addiction and referring to appropriate care 
centers (Moore, Jones, Browder, Daffron, and Passik, 2009). There is not currently one 
universal screening tool intended for use across all patient populations. There are, 
however, recommendations in place from the CDC and the American Society of 
Addiction Medicine (ASAM) that encourage clinicians to use at least one of the 
screening tools available to assess for opioid use and related risk in the general 
population. Most primary care offices for adult patient populations have incorporated 
screening tools into their initial assessment of the patient and continue to assess 
throughout their care length. If patients are identified as currently having, or as being at 
high risk for developing an opioid use disorder, clinicians are encouraged to implement 
evidence-based interventions as appropriate for each case. Examples of commonly 
utilized screening tools include the Screener and Opioid Assessment for Patients with 
Pain (SOAPP), the Opioid Risk Tool (ORT), and the Diagnosis, Intrac (NIDA, 2018). 
These screening tools vary in utilization based on patient population of each clinical site. 
One study performed by Moore, Jones, Browder, Daffron, and Passik, (2009), 




given to its utility and specificity. The second best validated tool was the ORT score, 
with increased feasibility  found in clinical settings (Moore, et al., 2009). Barclay, Owens 
and Blackhall (2014) utilized the ORT in their clinical practice due to its high sensitivity 
and specificity, especially with the combined assessment of results through clinical 
examination. They also noted that the ORT is the only screening tool to focus on family 
history and personal history of substance use (Barclay, et al., 2014). Overall, there is not 
one tool recommended over another and further research is required to standardize 
screening procedures. 
The ORT has been recommended by the Rhode Island Department of Health as a 
best practice measure for screening patients for opioid use disorders. The ORT is well 
validated, and is more feasible for use in the proposed study settings due to ease of 
administration and minimal time requirements for implementation. For these reasons, the 
ORT has been selected as the screening tool for this study. 
The ORT is a clinician or self-reported screening tool designed to assess adults, 
particularly in the primary care setting, for the potential abuse of prescribed opioid 
medications for acute or chronic pain. This tool should be administered before initiation 
of opioid therapy to determine future risk of opioid disordered behavior. The tool assigns 
point values differentiated by gender for family history of substance abuse, personal 
history of substance abuse, age group, history of preadolescent sexual abuse, and 
psychological disease presence. Higher scores are correlated with higher risk of 
disordered medication behavior and should alert the clinician that the abuse potential is 
high. The use of the ORT in clinical practice is intended to help clinicians weigh potential 




The ORT score was validated using a c-statistic, in which sensitivity and 
specificity are measured simultaneously. The c-statistic measures predictive ability of a 
prognostic model and, specifically for the ORT score, it is defined as the likelihood that a 
patient who exhibits an aberrant behavior will have a higher predicted risk of such a 
behavior than does a patient who does not exhibit such an aberrant behavior (Webster & 
Webster, 2006). C-statistics are interpreted as c = 0.5 suggesting no discrimination, 0.7 < 
c <0.8 is considered acceptable discrimination, 0.8 < c < 0.9 is considered excellent 
discrimination, and c >0.9 is considered outstanding discrimination (Webster & Webster, 
2006). The study found that the female prognostic model had a c statistic of 0.85 and the 
male model had a c statistic of 0.82 (Webster & Webster, 2006). These indicate the 
models had excellent discrimination and therefore, excellent validity when utilized in the 
clinical setting. 
Addressing the Epidemic 
 In addition to utilizing a screening tool, other best practice requirements for 
providers include reviewing the Prescription Drug Monitoring Program (PDMP) in the 
state of residence prior to initiating an opioid prescription, performing random urine 
toxicology screening on patients receiving controlled substances to evaluate for 
compliance with prescribed therapy and abstinence from substances that are not 
prescribed, and ensuring that there is a provider-patient controlled substance agreement in 
place for those patients receiving opioid prescriptions that explicitly describes the 
expectations of both parties (provider and patient) with regards to compliance with the 




 Multiple authors describe success with PDMP utilization in clinical practice. 
Total opioid prescriptions decreased with consistent provider monitoring of the PDMP in 
cases where patients were using or being considered for an opioid prescription (Rasubala, 
Pernapati, Velasquez, Burk, & Ren, 2015;  Ringwalt, Schiro, Shanahan, Proescholdbell, 
Meder, Austin, & Sachdeva, 2015). In addition, states using PDMP in their practices 
reported a smaller increase in opioid treatment admissions and lower mortality rates 
overall (Reisman, Shenoy, Atherly, & Flowers, 2009). Urine toxicology screens are also 
positively associated with compliance with prescribed substances and avoidance of non-
prescribed substances (Blum, Han, Femino, Smith, Saunders, Simpatico, Schoenthaler, 
Oscar-Berman, Gold, 2014). In this study, patients were found to be 12% more compliant 
with prescribed substances than baseline data one year earlier with the addition of urine 
toxicology screens (Blum, et al., 2014). 
Current guidelines set forth by the CDC and RIDOH may have limitations in 
predicting opioid use disorder or opioid overdose risk, and may have limited 
effectiveness in improving outcomes. Wei, Chen, Fillingim, Schmidt, and Winterstein 
(2019) posit that over 35% of commercially insured patients with OUD or opioid 
overdose had no opioid prescriptions filled within the last year per the PDMP, and those 
who did have opioid prescriptions filled were at a morphine milliequivalent lower than 
the CDC recommendation. In addition, not all states participate in the PDMP and 
information may not accurately cross state borders of those states who do (Griggs, 
Weiner, & Feldman, 2015). Griggs, Weiner, and Feldman (2015) also state that patients 
with fragmented care or undertreated care may have falsely assumed “suspicious” 




Colleen (2009) and Yarbrough (2018) challenged the effectiveness of a patient-
provider controlled substance agreement, noting that it may imply distrust of the provider 
and undermine the therapeutic relationship. Rager and Schwartz (2017) also challenge 
that a CSA may not be ethical if the patient is asked to sign whether while in pain or in an 
attempt to gain controlled medications. These authors note that “their consent has 
questionable legal and moral status” (Rager & Schwartz, 2017, p. 24). 
In addition, Collen (2009) noted that urine toxicology screening has low utility in 
the clinical setting. There is a large margin for error related to improper collection, 
transportation, and resulting of these tests, rendering them incorrect and ineffective for 
proper controlled therapy monitoring (Collen, 2009). Confirmatory testing, in which 
urines are sent out to a lab, takes almost one week to result, is more expensive to 
complete, and still often leads to false negative or positive results. Misinterpretations of 
these tests can lead to devastating outcomes for the patient, and patient-provider 
relationship. 
Despite the above limitations, interventions such as the CSA, PDMP, and urine 
toxicology screening have shown modest to low improvements in outcomes (Bonnie, 
Ford, & Phillips, 2017; Yarbrough, C., 2018). Overall, evidence around these 
interventions is positive, and they are currently considered the best practice under current 
national and local guidelines. Further research is needed to better establish the 
effectiveness of these interventions, and to continue to identify new practices that may 





Evaluating Effectiveness of Guidelines 
 Limited evidence describing the effectiveness of implementation strategies to 
translate evidence-based opioid prescribing and monitoring practices was found in the 
literature. Many providers lack confidence with opioid prescribing and report inadequate 
education related to the topic (Naimer, et al., 2019; Wei, et al., 2019). Specifically, 
academic family medicine teaching centers face challenges when it comes to opioid 
prescribing, including higher rates of opioid misuse in the resident patient population and 
lower levels of resident confidence and experience managing chronic non-cancer related 
pain (Naimer, et al., 2019).  
Several published quality improvement studies have demonstrated the successful 
implementation of evidence-based opioid prescribing guidelines into practice. One 
prominent study performed in 2016 implemented guidelines into primary care clinics via 
in person and electronic education. Pre-intervention data was obtained through chart 
review for patients receiving more than three opioid prescriptions. After guidelines were 
introduced, patient charts were retrospectively reviewed during the post-intervention 
period. Researchers found that patients receiving acute or chronic opioid prescriptions 
decreased (p = 0.02, p = 0.03), while urine toxicology screenings increased (p = 0.005) 
(Chen, Hom, Richman, Richman, Asch, Podchiyska, & Johansen, 2016).  
Naimer, Munro, Singh, and Permaul (2019) implemented and evaluated the 
HeLP, or “Healthy Living with Pain”, initiative aimed at improving family medicine 
resident opioid prescribing practices. Six core components were identified, to include a 
collaborative practice model, patient registry formation, resident education, clinical 




Implementation of these aspects into the clinical practice setting  led to better resident 
adherence to national practice guidelines and safer opioid prescribing (Naimer, et al., 
2019). This article was one of the first to demonstrate specific outcome measures related 
to resident prescribing practices. The authors call for further research demonstrating the 
ability to adapt and scale the model to other practice settings. 
Organizational Assessment/Local Problem 
Local Problem 
 Data collected by the National Institute on Drug Abuse reveals that there were 
277 opioid-related overdose deaths in Rhode Island in 2017, with an adjusted rate of 26.9 
deaths per 100,000 persons (NIDA, 2019). This is significantly higher than the national 
average in 2017, of 14.6 per 100,000 persons (NIDA, 2019). Deaths specifically 
involving fentanyl rose from 12 reported associated deaths in 2012 to 201 deaths in 2017 
in Rhode Island alone (NIDA, 2019), with a reported 28,466 patient deaths related to 
fentanyl throughout the United States (NIDA, 2019). While Rhode Island providers were 
below the national average for opioid prescriptions, at 51.2 per 100 persons and 58.7 per 
100 persons respectively, the ability to legally or illegally obtain opioids for Rhode Island 
residents increased tremendously (NIDA, 2019). This increase is connected to significant 
morbidity and mortality, demonstrated by rising overdose-related death rates. In addition, 
co-occurring disease rates are increasing as well. Specifically, 9% of the 40,000 new HIV 
diagnoses in the United States were attributed to intravenous (IV) synthetic opioid drug 
use (NIDA, 2019). In Rhode Island, 70 new cases of HIV occurred in 2017, with 11.8% 
male attribution to IV drug use, and 21.1% of female attribution to IV drug use (NIDA, 




national cases of acute Hepatitis C with 68.6% of these attributed to intravenous (IV) 
drug use (NIDA, 2019). In Rhode Island, there was an estimated 10,100 persons living 
with Hepatitis C in 2016, but specific data related to IV drug use was unavailable due to 
lack of reporting (NIDA, 2019). 
 In response to this upward trend in opioid-related deaths, the Rhode Island State 
Governor, Gina Raimondo, initiated a program in 2016 named the “Governor’s Task 
Force.” This taskforce is a committee established to reduce overdose deaths in Rhode 
Island by utilizing multiple techniques towards a goal of reducing opioid-related deaths 
by one third in three years (Prevent Overdose RI, 2019). The action plan associated with 
this committee involves four major components including prevention, rescue, treatment, 
and recovery.  
 To address the taskforce’s action plan, the Rhode Island Department of Health 
(RIDOH) put forth guidelines for providers to follow when prescribing an opioid. These 
guidelines are in alignment with those set forth by the American Society of Addiction 
Medicine (ASAM), which aim to support evidence-based prescribing practices (RIDOH, 
2019). The RIDOH recommends completing a full medical history and physical 
examination on each patient, including  assessment of pain characteristics, physical and 
psychological functioning, personal and family history of substance abuse, coexisting 
conditions, and determination of the indication for the use of a controlled substance 
(RIDOH, 2019). According to these guidelines, patients should be screened annually to 
assess for the presence of substance abuse. Individuals demonstrating current substance 
abuse should be referred to treatment. Prior to prescribing opioid medications, the 




balancing risks and expected benefits. This plan should be implemented in the form of a 
controlled substance agreement that is signed by both the provider and patient. Once an 
opioid prescription is determined to be necessary, the provider should have the patient 
sign an informed consent form, review the prescription drug monitoring program 
(PDMP), co-prescribe naloxone, and frequently reassess the patient for the continued 
need for opioids (RIDOH, 2019).  
 Prior to the implementation of this project, the practice setting did not routinely 
use screening methods for opioid use disorders, and implementation of PDMP checks, 
urine toxicology testing, and patient contracts was inconsistent. Improving compliance 
with these best practice measures is essential to optimizing outcomes related to OUD.  
Organizational Assessment 
An analysis was completed prior to the implementation of the project to identify 
potential strengths, weaknesses, opportunities and threats (SWOT). Strengths of the 
project relate to the internal factors that would benefit the project and contribute to its 
success. Strengths identified in this project included the availability of the intended 
patient population, with a majority of patients at the clinical site seeking care for pain 
management or substance use needs. Providers in the practice setting were easily engaged 
in the project, and there was strong support for the implementation of best practice for 
minimizing OUD among administrators at the organizational level. Given the limited 
compliance with best practice recommendations and the lack of current improvement 
initiatives related to this problem, there was a strong need for this project. Providers at 
the practice setting were already familiar with the use of evidence-based practice 




use of such protocols facilitated the implementation of the RIDOH guidelines and ORT 
assessment. In addition, due to increasing national attention to the opioid epidemic, the 
public is increasingly aware of risks associated with opioid use, potentially increasing 
their willingness to follow prescriber recommendations.  
Weaknesses refer to the internal factors that threaten the success of the project. 
Although engagement among administrators and providers was generally high, the 
potential for decreased administrative or provider engagement at any of the clinical sites 
was a risk. More specifically, there was a risk that providers may be resistant to changes 
in current practice or may view the time required for participating in the education 
sessions as either a distraction or loss of billable hours. Providers may have also felt that 
their discretion regarding the use of opioid prescriptions for patients with pain 
management needs was in question. In addition, staff turnover presented another 
challenge, with residents routinely rotating through the practice setting. To minimize the 
impact of turnover, the intervention was completed between resident rotation changes. 
Opportunities are defined as external factors that increase social engagement in the 
project. Related to this project, a strong national public health initiative to reduce illicit 
opioid use and subsequent overdose risk was a major leverage point. At the state level, 
the RIDOH initiatives and creation of the Governor’s Task Force has significantly 
increased the amount of public awareness given to the topic of opioid use and overdose-
related deaths. It was thought that the presence of positive local and national attention 





Threats are described as external factors that may challenge the project goals. A 
major threat to this project included the presence of advocacy groups that have been 
forming to vocalize the need for increased pain management. These groups feel that 
restrictions on opioid prescribing are detrimental to the management of pain. Increasing 
resistance among groups opposed to the implementation of evidence-based opioid 
prescribing practices may contribute to provider fear of potential lawsuits or negative 
publicity regarding the provider or facility, thereby undermining project goals. 
Problem Statement and Study Question 
Currently available evidence suggests that provider adherence to best practices is low 
(ASAM, 2015; Naimer, et al., 2019). As the numbers of patients with opioid use disorder 
and subsequent overdoses rise, it is imperative that providers incorporate evidence-based 
prescribing and patient management practices into their practice. Optimizing outcomes 
related to opioid use disorders depends on the consistent implementation of best practices 
by providers in all care settings. 
Purpose Statement and Specific Aims 
The purpose of this project was to facilitate recognition of patients at high risk for 
opioid use disorders and facilitate best evidence-based practice in the care of this 
population. The specific aims were to achieve provider compliance with the 
implementation of best practice guidelines including 
1. Opioid risk screening via ORT  
2. Implementation of PDMP review, signed care plans, and urine toxicology 
screening and,  





Kurt Lewin’s Change Theory was developed in 1940 and identifies three distinct 
stages of behavior change (Petiprin, 2016). The Change Theory involves the concepts of 
driving forces, restraining forces, and equilibrium that relate to the change in behavior 
stages. Driving forces are those that push one in the direction of change, allowing 
acceptance of the change that will occur. Restraining forces, conversely, are those that 
hinder or oppose the change. Equilibrium is a state of being where driving forces are 
equal to restraining forces. When driving and restraining forces are in equilibrium driving 
forces are unable to overcome restraining forces, therefore, change will not occur. To 
lead change, the key forces related to the desired change are identified and manipulated 
so that driving forces are increased over restraining forces (Petiprin, 2016).  
In regards to the proposed project, an initial assessment was employed to identify 
outdated or ineffective prescribing and assessment techniques with co-identification of 
driving and restraining forces for the adoption of new techniques. Change was facilitated 
by minimizing restraining forces and working to ensure that the reason for the intended 
change was perceived as beneficial to the participants. Work to establish refreezing is 
ongoing and will occur when the intervention becomes part of standardized practice and 
best practice adoption is identified in all appropriate clinical situations. Appendix C 
demonstrates the forcefield analysis for this project. 
Another framework used to support this project was the middle range theory, the 
Theory of Pain: A Balance between Analgesia and Side Effects (Good, 2013). This 
theory describes the balance between efforts to increase patient satisfaction with relief 




Pharmacologic measures to alleviate pain may include opioid or non-opioid pain 
medications, while non-pharmacologic pain measures may include any adjunct therapies 
known to alleviate pain or suffering, such as massage, imagery, music, or relaxation 
techniques (Good, 2013). The provider is required to perform adequate and regular 
assessments of pain and side effects at particular intervals with a mutually agreed-upon 
goal in mind. If the number and intensity of adverse effects are unacceptable to either 
party, the therapy is discontinued. The absence of reported adverse effects would be an 
ideal outcome for the patient and provider. Adverse effects from therapies may include a 
variety of unpleasant occurrences, ranging from acute gastrointestinal distress to the 
development of an addiction to a prescribed substance. Patient education is an important 
aspect of the theory and provides encouragement and instruction regarding expectations, 
actions, and mutually agreed upon, safe goals for relief (Good, 2013). 
 This theory may be applied to patients receiving chronic or acute opioid therapy 
in a primary care office setting for any number of conditions, as it addresses the complex 
balance of risks and benefits associated with high-risk medications. Patients experiencing 
pain seek relief, and practitioners treat pain with a variety of therapies with the intention 
of providing a reduction in pain and improvement in quality of life. If a provider feels an 
opioid prescription is a necessary component of the treatment plan, consistent evaluation 
of medication efficacy will be required to determine if the benefits of therapy are 
outweighing the risks associated with the controlled substance. If the patient is 
experiencing significant side effects or adverse reactions, including substance misuse, 
that outweigh analgesia, the provider should consider discontinuation of the therapy to 






The project took place in a primary care practice within the Care New England 
Medical Group. The practice focuses on internal medicine and is located in an urban area 
with a large patient population. This practice consists of a resident clinic, with first, 
second, and third-year resident physicians who rotate through this setting. Each resident 
is supervised by an attending physician, and each attending physician is responsible for 
supervising five residents per shift. Each provider working in these settings usually 
performs visits on eighteen to twenty patients per day. These patients are seen in the 
office for a multitude of complex care needs, including managing chronic and acute pain 
needs. Patients are all age 18 and older.  
Participants 
This project involved the education of providers regarding implementation of the 
ORT and best practices in the management of patients at risk for opioid use disorder. 
Outcomes related to compliance at the patient and provider level, as previously described, 
was evaluated by retrospective chart review. Providers who were actively employed by 
the specified clinical site were included in the educational intervention. These providers 
consist of resident physicians (n = 15) and attending physicians (n = 8). Data related to 
patient compliance was collected by retrospective chart review of adult patients receiving 
treatment for acute or chronic pain, or who were identified as being at-risk for, or were 
receiving treatment for a substance use disorder. No patient identifiers were collected and 





Baseline data was collected by retrospective chart review for a two-month period 
prior to the intervention (June to July 2019). The primary investigator (PI) independently 
screened all charts at the clinic for the above criteria. Specific data collected included 
compliance with ORT implementation, controlled substance agreements, PDMP review, 
and number of inappropriate opioid prescriptions. Following collection of baseline data, 
the PI delivered an educational program (October 2019) addressing the ORT, ASAM, and 
RIDOH guidelines for safe opioid prescribing practices and the potential benefits of 
compliance with these measures. The education was delivered in the form of a 
PowerPoint presentation and paper handouts were provided to reinforce teaching points. 
Education was delivered to providers in half-hour time slots dedicated to the project, as 
had been approved by the office manager. The educational sessions occurred during 
resident learning times or attending administrative times, thereby reducing the loss of 
clinical time. Provider participation was voluntary.  
The intervention period continued for three months (October to December 2019), 
after which the PI collected post-intervention data for the immediate period following the 
intervention. Data was monitored for short-term sustainability of outcomes through May 
2020. Appendix A demonstrates the complete timeline for project implementation and 
evaluation. 
Measures and Analysis 
Pre- and post-intervention data was collected by retrospective chart review. 
Demographic data was reported using descriptive statistics. Differences between pre- and 




aggregate level data, no patient identifiers were collected. Goals were to increase 
provider compliance with evidence based opioid prescribing practices. 
Ethical Considerations 
This project was reviewed and approved by both the organizational and 
educational setting’s Institutional Review Boards (IRB). Waiver of informed consent was 
requested and was granted by the IRB, as this quality improvement project involved the 
implementation of established best practices and did not involve risk beyond that 
associated with routine practice. Participation in the education sessions was strictly 
voluntary and there were no penalties for lack of participation.  
Results 
Data collected in the post-implementation period demonstrated an increase in 
guideline implementation. Urine toxicology monitoring increased from 73.86% to 95.8% 
compliance (p = 0.002), PDMP review increased from 42.11% to 62.50% compliance (p 
= 0.12), and CSA in place increased from 42.11% to 58.33% compliance (p = 0.13). The 
number of cases in which two or more measures were simultaneously implemented rose 
from 36.84% to 54.17% (p = 0.10). New opioid prescriptions decreased from 5.26% to 
4.17%, meaning less new opioid initiations took place. Because the ORT had not been 
implemented prior to the intervention, compliance with this measure was 0% at baseline. 
Implementation of the ORT was not achieved during this project with compliance 
remaining at 0% after the intervention. Urine toxicology monitoring had a statistically 























Pre and Post Intervention Compliance with Best Practices 
 
Discussion 
This quality improvement study was performed to facilitate implementation of 
best practice guidelines. Although current guidelines are well established, limited quality 
improvement studies exist to inform the effectiveness of interventions to consistently 
implement these guidelines in practice. This project demonstrated strong improvements 
in all areas, except for the implementation of patient screening utilizing the ORT. 
Overall, improvements ranged from 20% to 48%. All improvements were clinically 
significant. Although a lack of patient screening using the ORT continued during the 
post-intervention period, this did not appear to impact implementation of other practices. 
It is unknown if patient screening would have further increased improvements in urine 
toxicology screening, PDMP review and implementation of CSAs. Further research is 




was noted in all areas, the only statistically significant improvement was noted in urine 
toxicology screening. However, the sample size for this project was small. Statistical 
significance in other areas may have been reached with a larger sample. 
Strengths associated with this project included strong support of leadership and 
participating providers for project initiation and implementation. There was a measurable 
positive provider response to education seen in improvements in guideline 
implementation. There was an increased awareness among providers of evidence-based 
guidelines and the rationale for consistent implementation. Overall, a clear improvement 
in practice was noted in the clinical setting. 
Limitations associated with the project included a short implementation time. In 
addition, this project was limited to a single setting and had a small sample size. The 
education took place in a resident clinic, in which residents were already inundated with 
weekly education seminars related to their program. Real-time auditing and feedback was 
planned, but was unable to be performed due to time constraints. There was also a lack of 
inclusion of ancillary staff in the intervention, which may have further improved urine 
toxicology monitoring as medical assistants were primarily responsible for ensuring this 
was performed.  
Sustainability and Scalability 
 
Sustainability is defined as locking in the progress made by an improvement 
initiative and adapting and spreading the initiative to other areas so that the greatest 
number of patients will benefit (Moran, Burson, & Conrad, 2020). This is often 
accomplished by first disseminating information about successful interventions and 




(Moran, Burson, & Conrad, 2020). Sustainability requires obtaining input and buy-in for 
continued project support of the initiative from all key stakeholders and decision-makers. 
Short- and long-term objectives must be explicitly defined and determined so that a 
common goal is shared among all stakeholders (Moran, Burson, & Conrad, 2020). 
Resources required for this project included administrative support for provider 
participation and time of the investigator devoted to the continuation of the project.  
 The NHS Sustainability Model and Guide provides a practical resource for 
assessing and planning for optimal project sustainability (Maher, Gustafson, & Evans, 
2017). The sustainability model consists of ten factors relating to staff, processes, and 
organizational issues (Maher, Gustafson, & Evans, 2017). This model was used to 
identify strengths and weaknesses during the planning phases of this project so that 
appropriate strategies could be implemented to optimize the chances of sustainability of 
the project. Sustainability was reassessed upon completion of the project (see Appendix 
D). 
Conclusion 
This project introduced evidence-based practice guidelines into a clinical setting 
where compliance was poor and measures were under-utilized. The intervention led to 
improved outcomes related to compliance with best practices in opioid prescribing. There 
is a need for ongoing work to adapt and scale this quality improvement project across 
multiple practices within this and other healthcare settings. There is a need for continued 
education for providers and members of the multi-disciplinary team to ensure 




community about the rationale for these guidelines and benefits associated with 
implementation. 
Future research should be performed to determine the relationship between risk 
assessment and screenings with regards to guideline implementation. The impact of 
including office staff in the education sessions, as well as the impact of implementing 
real-time auditing and feedback throughout the project, should be further explored in 
future studies. Future practice scholarship should also be targeted at improving long-term 
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Table 1: Cost-Benefit Analysis 
Costs Associated with Project 
Category Details Cost in 1 year 
Paper Materials 
- Paper handouts 
- Printing expenses 
- Copying expenses  
Paper supplies, printing 
costs, and copying 
expenses will need to be 
considered in order to 
provide providers with 
handouts related to the 
subject material 
$20-$30 
Travel Expenses Gas utilized for the travel 
time of the primary 
investigator between 
clinical site locations 
$20-40 
Time Time will be required by 
the primary investigator to 
create the educational 
materials, as well as 
clinical site providers will 
need to utilize 
administrative time to 
attend sessions 
Sessions will be held 
during pre-scheduled 
administrative times so 
clinical time will not be 
utilized. Productivity is not 




Benefits Associated with Project 
Benefit Benefits within 12 Months 
Increased provider knowledge of 
nationally recognized guidelines to 
manage controlled substances 
Utilization of tools will increase provider 
cognizance of individual patient risk and 
positively impact treatment decisions 
Increased integration and compliance with 
guidelines 
Compliance with mandatory guidelines 
improves quality of care  
Decreased inappropriate opioid initiations 
and generalized reduction in publicly 
circulating opioids 
Improves patient and public safety with 
decreased access to controlled substances 
Decrease incidence of OUD and overdose Increases patient safety, decreases 
potentially life-threatening emergencies 



















Table 3: Sustainability Assessment 
Modified from the NHS Sustainability Model and Guide (Maher, Gustafson, & Evans, 
2017) 
Process 
Factor Score Description Evaluation 
Benefits beyond 
helping patients 
8.5 We can demonstrate that 
the change has a wide range 
of benefits beyond helping 
patients, for example, by 
reducing waste, creating 
efficiency, or making 
people’s jobs easier 
Development of an 
ORT score for easy 
clinical utilization 
Credibility of the 
benefits 
9.1 Benefits of the change are 
widely communicated, 
immediately obvious, 
supported by evidence, and 
believed by stakeholders. 
Staff is fully able to 
describe a wide range of 
intended benefits for this 
initiative. 
Notable increase in 
clinical guideline 
use with increased 




3.4 The improved process can 
be adapted to support wider 
organizational change but it 
would be disrupted if 
specific individuals or 
groups left the project. 
Elements of this work will 
continue to meet our 
organization’s 
improvement needs. 
Will need sustained 
efforts to continue 
utilization in clinical 
practice. Will benefit 
from spread to other 
clinical sites within 
the practice setting. 
Effectiveness of the 
system to monitor 
progress 
3.3 There is a system in place 
to provide evidence of 
impact, including benefits 
analysis, monitor progress, 
and communicate the 
results. This is not set up to 
continue beyond the formal 
life of the project. 
Will require a 
monitor moving 
forward to continue 
chart assessment for 
utilization 
Staff 
Staff involvement and 
training to sustain the 
process 
4.9 Staff have not been 
involved from the 







but they have received 
training in the new way of 
working 




towards sustaining the 
change 
11.0 Staff is able to share their 
ideas regularly and some of 
them have been taken on 
board during the project. 
They believe that the 
change is a better way of 
doing things and have been 
empowered to run small 
scale test cycles (PDSA) 
Staff will engage in 






15.0 Organizational leaders are 
highly involved and visible 
in their support of the 
change process. They use 
their influence to 
communicate the impact of 
the work and to break down 
any barriers. Staff regularly 
shares information with and 
actively seek advice from 
leaders. 
Senior leadership 
will continue to 
support staff efforts 
to continue research 




15.0 Clinical leaders are highly 
involved and visible in their 
support of the change 
process. They use their 
influence to communicate 
the impact of the work and 
to break down any barriers. 
Staff regularly shares 
information with and 
actively seek advice from 
clinical leaders. 
Clinical leaders will 
collaborate with 






Fit with the 
organization’s 
strategic aims and 
culture 
7.0 The goals of the change are 
clear and have been widely 
spread. They are consistent 
with and support the 
organization’s strategic 




improvements before and 
has a “can do” culture.  
There is a 
measurable change 
in patient and 
provider outcomes 
that will support the 





Infrastructure 4.4 Staff is confident and 
trained in the new way of 
working. However, job 
descriptions, policies, and 
procedures do not yet 
reflect the new process. 
Some communication 
systems are in place. 
Facilities and equipment 
are all appropriate to 
sustain the new process.  
This author will 
continue to help staff 
navigate clinical 
guidelines  
Process Total (24.3) + Staff Total (45.9) + Organization Total (11.4) = 


























Table 4: Opioid Risk Tool (ORT) Sample 
Mark each box that 
applies 
Female Male 
Family history of substance abuse 
Alcohol 1 3 
Illegal Drugs 2 3 
Rx Drugs 4 4 
Personal history of substance abuse 
Alcohol 3 3 
Illegal drugs 4 4 
Rx drugs 5 5 
Age between 16-45 years 1 1 
History of preadolescent 
sexual abuse 
3 0 
Psychological disease   
ADD, OCD, bipolar, 
schizophrenia 
2 2 
Depression 1 1 

















Score of 3 or lower à low risk for future opioid abuse 
Score of 4 to 7 à moderate risk for future opioid abuse 
Score of 8 or higher à high risk for future opioid abuse 
 
